在高容量转移性割敏感前列腺癌中,在化疗后进行多西素再挑战
Kenichi Hata1, Yuki Takiguchi2, Yuya Iwamoto2
1Department of Urology, Shonan Keiiku Hospital, Fujisawa, JPN.
Cureus
|September 29, 2025
概括
在先前的化疗激素治疗后,多西塔克塞尔重试 (DR) 在转移性割抵抗性前列腺癌 (mCRPC) 患者中显示出有限的临床益处. 需要进一步的研究来确定其作用和患者选择标准.
科学领域:
- 在瘤学瘤学.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 临床研究 临床研究
背景情况:
- 多塞塔克塞尔是转移性前列腺癌的标准治疗方法.
- 有限的数据存在于 docetaxel 重复挑战 (DR) 疗效在转移性割抵抗性前列腺癌 (mCRPC) 在先前的化学激素治疗大容量转移性割敏感前列腺癌 (mCSPC) 后.
研究的目的:
- 评估dcetaxel重试 (DR) 的临床结果,在mCRPC患者中,这些患者先前接受过化学激素治疗,以治疗大量的mCSPC.
主要方法:
- 对32名用化疗激素治疗的高容量mCSPC患者的回顾性审查.
- 对5名患者的分析,在进展到mCRPC后接受了DR.
- 评估患者的特征,前列腺特异性抗原 (PSA) 水平和不良事件.
主要成果:
- 随访时间中位数为26个月;DR开始时的中位数年龄为74岁.
- 两个接受DR作为一线mCRPC治疗的患者 (40%) 实现了≥50%的PSA下降.
- 3级疲劳发生在两名患者身上;脱发是最常见的不良事件.
结论:
- 杜塞塔克塞尔重试 (DR) 可能在选择的mCRPC患者中提供有限的临床益处,治疗选择受到限制.
- 由于样本规模较小和响应变异性,DR的治疗作用仍然不确定.
- 未来研究是必要的,以确定DR的临床价值,并建立患者选择标准.
更多相关视频
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.7K
08:04In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
Published on: February 27, 2019
12.4K
相关概念视频
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
814
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
814
